A Drug Used by Thousands Every Year
Pemetrexed is a chemotherapy drug used to treat non-squamous non-small cell lung cancer and a rare cancer called malignant pleural mesothelioma. It works by blocking certain chemical pathways that cancer cells need to grow and divide.
It has been in use since the early 2000s and is part of many standard treatment regimens. Millions of doses have been administered worldwide. Known side effects — like low blood counts and kidney stress — are managed with vitamin supplements and careful monitoring.
The Side Effect Picture Was Incomplete
Doctors have long known that pemetrexed can affect the blood and kidneys. But researchers suspected the full profile of potential adverse effects had not been fully mapped.
But here's the twist: when scientists analyzed 20 years of FDA adverse event reports, they found signals pointing to dozens of side effects that weren't on the official label — including some involving the immune system and hormone-related organs.
How Drug Safety Signals Are Detected
The FDA maintains a massive database called FAERS (FDA Adverse Event Reporting System). Think of it as a nationwide suggestion box where doctors, patients, and pharmacists report unexpected health events that happen while someone is taking a drug.
Researchers don't take these reports at face value. They run statistical tests to identify which side effects appear far more often with a specific drug than you'd expect by chance — a process called disproportionality analysis. A strong signal doesn't prove the drug caused the problem, but it flags areas that need attention.
What the Analysis Covered
This study pulled every pemetrexed-related report from the FAERS database between 2004 and 2024 — a total of more than 27,000 reports. Researchers then ran multiple statistical methods to identify meaningful safety signals across every organ system in the body.
Unexpected Patterns in the Data
The strongest known signals involved blood disorders — confirming what doctors already monitor closely. But researchers also found a strong signal in endocrine (hormone-related) disorders, which was not previously labeled. Other unlisted signals included colitis (inflammation of the colon), oral lesions, immune-mediated pancreatitis, and a form of kidney inflammation called tubulointerstitial nephritis.
The analysis also revealed timing patterns. More than half of all reported side effects occurred within the first 30 days of treatment. A smaller second wave appeared roughly six months to a year later — suggesting some delayed reactions that might otherwise be overlooked.
This does not mean every patient on pemetrexed will experience these effects — these are signals, not certainties.
Different Risks for Different People
An important finding was that men and women appeared to face different risk profiles. Men showed stronger signals for respiratory (breathing-related) complications. Women showed stronger signals for kidney injury. Age-related differences were also observed. These patterns suggest that one-size-fits-all monitoring may not be the best approach.
If you are currently taking pemetrexed or are about to start, this study does not mean you should stop or panic. It means your care team should be aware that unusual symptoms — especially involving hormones, the digestive system, or kidneys — may be worth investigating rather than dismissing. Bring up any new symptoms with your oncologist, especially in the months after treatment begins and again around the six-month mark.
The Limits of This Type of Study
FAERS data has real limitations. Reports are submitted voluntarily, so not all side effects are captured. The database cannot confirm that pemetrexed caused a specific event — only that the event was reported in someone taking pemetrexed. Confounding factors like other drugs or underlying conditions cannot be fully controlled for.
Where This Research Goes Next
The researchers call for prospective studies — carefully designed trials that follow patients from the start and systematically track side effects over time. If these signals are confirmed in those settings, drug labeling may be updated and clinical monitoring guidelines revised. That process takes time, but this kind of pharmacovigilance work is exactly how drug safety evolves after a treatment reaches widespread use.